Literature DB >> 20924143

Serum retinol, alpha-tocopherol and systemic inflammatory response in metastatic colorectal carcinoma patients treated with combination chemotherapy and cetuximab.

Bohuslav Melichar1, Lenka Krcmová, Hana Kalábová, Petra Holecková, Markéta Kasparová, Jirí Plísek, Radomír Hyspler, Hana Studentová, Dagmar Solichová.   

Abstract

Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma. Cancer and anticancer therapy are associated with oxidative stress, and disorders of antioxidant balance may be involved in the toxicity associated with anticancer treatment. The aim of the present study was to investigate the changes of serum retinol, alpha-tocopherol and C-reactive protein during the first month of treatment with cetuximab and chemotherapy. Twenty-five consecutive patients with metastatic colorectal carcinoma treated with a combination of chemotherapy and cetuximab were included in the present study. Serum retinol and alpha-tocopherol were determined by high-performance liquid chromatography and serum C-reactive protein was determined using commercial kits. Significant correlation was observed between baseline concentrations of retinol and C-reactive protein (r(s)=-0.54, p<0.01). Median survival of patients who had baseline serum retinol below 1.25 µmol/L was 10 mo compared to 18 mo for patients who had serum retinol equal or above 1.25 µmol/L (p<0.05); median survival of patients who had serum C-reactive protein below 24 mg/L was significantly longer compared to patients with C-reactive protein levels equal or above 24 mg/L (18 vs. 7 mo, p<0.05), but no difference in survival was observed based on alpha-tocopherol levels. Twenty-two patients had evaluation of retinol, alpha-tocopherol and C-reactive protein at least once during the follow up. Serum concentration of alpha-tocopherol decreased significantly during the therapy, but retinol and C-reactive protein concentrations remained unchanged. In conclusion, a significant correlation was observed between serum retinol and C-reactive protein. Serum alpha-tocopherol decreased significantly during the first month of combination therapy with cetuximab. Low retinol and high C-reactive protein concentrations were predictive of poor prognosis in this patient population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924143     DOI: 10.3177/jnsv.56.222

Source DB:  PubMed          Journal:  J Nutr Sci Vitaminol (Tokyo)        ISSN: 0301-4800            Impact factor:   2.000


  5 in total

1.  C-reactive protein, lipid-soluble micronutrients, and survival in colorectal cancer patients.

Authors:  Robert V Cooney; Weiwen Chai; Adrian A Franke; Lynne R Wilkens; Laurence N Kolonel; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05-15       Impact factor: 4.254

2.  Neutropenic diet and quality of food: a critical analysis.

Authors:  Adriana Garófolo
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 3.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

4.  Dose-Response Relationship between Serum Retinol Levels and Survival in Patients with Colorectal Cancer: Results from the DACHS Study.

Authors:  Haifa Maalmi; Viola Walter; Lina Jansen; Robert W Owen; Alexis Ulrich; Ben Schöttker; Jenny Chang-Claude; Michael Hoffmeister; Hermann Brenner
Journal:  Nutrients       Date:  2018-04-19       Impact factor: 5.717

5.  Poor Vitamin Status is Associated with Skeletal Muscle Loss and Mucositis in Head and Neck Cancer Patients.

Authors:  Sara Nejatinamini; Brock J Debenham; Robin D Clugston; Asifa Mawani; Matthew Parliament; Wendy V Wismer; Vera C Mazurak
Journal:  Nutrients       Date:  2018-09-05       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.